New trial
Phase II Mirvetuximab Soravtansine ADC, FOLR1-directed tubulin inhibitor
- Trial ID
- NCT04606914 on ClinicalTrials.gov
- Cancer type
- Ovarian Cancer
- Published in
- New in Oncology - June 16, 2025
This single-arm Phase II trial at University of Alabama at Birmingham evaluates neoadjuvant carboplatin plus mirvetuximab in advanced-stage serous ovarian cancer with high FRα expression. The study documents treatment feasibility before interval surgery with flexible maintenance options, including standard regimens for BRCA-mutated patients.
More in ovarian cancer
-
Trial result · Oct 22, 2026 · NCT07213804
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy -
New trial · Oct 15, 2026 · NCT07851025
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer -
New trial · Oct 15, 2026 · NCT07504588
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression -
New trial · Oct 15, 2026 · NCT07776691
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab -
New trial · Oct 8, 2026 · NCT07816666
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload